Jodi Devlin - 30 Aug 2023 Form 4 Insider Report for TriSalus Life Sciences, Inc. (TLSI)

Reporting relationship: President, Therapeutics
Issuer ticker: TLSI
Reported as of: 30 Aug 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 31 Aug 2023, 21:04:03 UTC
Prior SEC filing: 31 Aug 2023
Next SEC filing: 14 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Mary Szela, Attorney-in-Fact for Jodi Devlin

Key filing fact

Jodi Devlin filed Form 4 for TriSalus Life Sciences, Inc. (TLSI) on 31 Aug 2023.

Key facts

This page summarizes Jodi Devlin's Form 4 filing for TriSalus Life Sciences, Inc. (TLSI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 31 Aug 2023, 21:04.

Change

Previous filing in this sequence was filed on 31 Aug 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TLSI transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +195,000
Change %
Price: $0.000000
Shares after: 195,000
Date: 30 Aug 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 195,000
Exercise price: $6.70
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of August 28, 2023, and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the vesting commencement date.